Menu

Dr. Clay Siegal: Powering 21st Century Cancer Treatments July 2, 2018

Hard work, the essential ingredient that has turned Seattle Genetics into a biotech force. A confessed work-a-holic, Dr. Clay Siegall tells the story of Charles Darwin in a letter to his cousin. Darwin did not believe there was any difference in man’s IQ, the difference was in work habits and focus.

Dr. Siegall found the inspiration to start Seattle Genetics by the brutal treatment regimen a family member was forced to endure. Treatments and complications the family member had to face were often far worse than cancer.

Seattle Genetics began life with the express intent on developing new and different approaches to cancer treatment. Dr. Siegall believes old-guard therapies, specifically systemic chemotherapies are destined for history. Dr. Siegal first became interested in treating cancer while studying zoology. Dr. Siegal received his BS in Zoology from the University of Maryland.

The firm has the first FDA approved antibody-drug conjugate ADCETRIS® along with 20 other drugs in the pipeline. Built on a platform of research and innovation the company has a passion for helping patients.

A collaboration with Takeda Pharmaceutical Company has propelled ADCETRIS® into a brand known the world over. The antibody-drug conjugate technology is now in over 20 different clinical trials.

From a tiny drug firm in 1998 to a dominant 21st-century powerhouse, Seattle Genetics is finally starting to make money. Dr. Siegal is very proud of his employees and the sales staff who have powered the growth. The deals put together take time and are usually in the seven to eight figures.

Dr. Siegal has a long history of research to find therapies for cancer treatment. From 1991 to 1997 Siegal was with Bristol Myers Squibb. He spent two years at the National Cancer Institute before he started Seattle Genetics. Siegal received his Ph.D. in Genetics from George Washington University.

Dr. Clay Siegal has powered Seattle Genetics to a world power in drug discovery. Under Clay’s leadership, the strategic partnership’s with AbbVie, Genentech, and GlaxoSmithKline have generated over $375 million to date. From a small start-up years ago, to a company that secured $1.8 billion in public and private funding.

Dr. Clay Siegal and Seattle Genetics will be a force in drug discovery for years to come.

Categories Cancer Treatment